X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersGlobeNewsWire • 10/09/26
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVenturesGlobeNewsWire • 10/08/26
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/01/26
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a TurnaroundZacks Investment Research • 09/24/26
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 09/11/26
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare ConferenceGlobeNewsWire • 09/09/26
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/07/26
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/26
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/07/26
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsGlobeNewsWire • 07/01/26
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/27/26
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' NowZacks Investment Research • 05/20/26
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/18/26
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/26
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/06/26
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionGlobeNewsWire • 04/29/26
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/17/26
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/17/26
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention24/7 Wall Street • 03/09/26
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare ConferenceGlobeNewsWire • 03/04/26
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA ApprovalSeeking Alpha • 03/03/26
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeGlobeNewsWire • 02/27/26
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptSeeking Alpha • 02/16/26